Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-01 + Azacitidine in Relapsed/Refractory MDS and AML
NCT02995655Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dociparstat sodium in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Washington University School of Medicine. Primary endpoint: Overall Response Rate. Started Apr 2017; status: completed.
02
Drugs
dociparstat sodium
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02995655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995655.